乳腺癌
转移性乳腺癌
化疗
医学
肿瘤科
内科学
内分泌系统
癌症
药品
结合
抗药性
药理学
生物
激素
微生物学
数学
数学分析
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2022-10-04
卷期号:: OF1-OF1
标识
DOI:10.1158/2159-8290.cd-nb2022-0061
摘要
The antibody–drug conjugate sacituzumab govitecan, or SG, may be a viable option for patients with metastatic HR-positive/HER2-negative breast cancer who have developed resistance to endocrine drugs. In the phase III TROPiCS-02 trial, compared with standard chemotherapy, SG extended both progression-free and overall survival, besides improving quality of life.
科研通智能强力驱动
Strongly Powered by AbleSci AI